Gapping down
In reaction to earnings/guidance:
TKR -1% (withdraws full year guidance; expects lower sales and earnings in 2H21 relative to prior expectations)
Other news:
AERI -17.1% (reports positive topline results of Phase 2b COMET-1 study for AR-15512)
SBTX -13.8% (Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab)
TIL -4.1% (presents subset analysis of patients with checkpoint-refractory advanced melanoma from compassionate use study at 2021 ESMO Congress)
RIO -2.7% (provides update on tax penalty assessment)
LIFE -2.6% (stock offering)
SRGA -1.4% (names new non-executive Chair of the Board)
AHT -1.1% (provides update on recent operating performance)
VXRT -1.1% (entered into $100 mln Controlled Equity Offering)
TVTX -1% (announces joint collaboration and licensing agreement with Vifor Pharma for sparsentan)
Analyst comments:
BYND -3.2% (downgraded to Underweight from Neutral at Piper Sandler)
LVS -2.6% (downgraded to Neutral from Overweight at JP Morgan)
FSR -2% (downgraded to Neutral from Buy at BofA Securities)
MLCO -1.5% (downgraded to Neutral from Overweight at JP Morgan)
LEA -1.4% (downgraded to Underperform from Neutral at BofA Securities)
VC -1.4% (downgraded to Underperform from Neutral at BofA Securities)
RIDE -1.3% (downgraded to Underperform from Neutral at BofA Securities)
EQNR -1% (downgraded to Hold from Buy at Deutsche Bank)